Anhui Anke Biotechnology (Group) Co., Ltd.

Anhui Anke Biotechnology (Group) Co., Ltd. saw a notable stock decline today, contrasting with a slight increase in the China Shanghai Composite. The company has faced challenges, reporting low net sales and operating profit, alongside a year-to-date decline and a significant drop over the past year.

Anhui Anke Biotechnology (Group) Co., Ltd. saw a significant intraday increase on August 13, 2026, contrasting with a decline in the China Shanghai Composite. Despite a recent weekly gain, the company has struggled over the past year, with a notable decrease in stock value and consistent underperformance against the benchmark index.

Anhui Anke Biotechnology (Group) Co., Ltd. saw a significant stock decline today, contrasting with the broader market's performance. The company has faced challenges, including a year-to-date decline and negative returns over the past three years, despite a high dividend yield and a large market capitalization in the biotechnology sector.

Anhui Anke Biotechnology (Group) Co., Ltd. experienced notable intraday gains, contrasting with a decline in the broader market. The company has shown a weekly increase and a significant monthly rise, though it faces longer-term challenges with declines over the past year and year-to-date. Its market capitalization is CNY 9,218 million.

Anhui Anke Biotechnology (Group) Co., Ltd. has seen a significant rise today, contrasting with the modest increase of the China Shanghai Composite. Despite recent gains, the company has faced challenges over the year and decade, maintaining a market capitalization of CNY 9,218 million and a dividend yield of 3.14%.

Anhui Anke Biotechnology (Group) Co., Ltd. saw a significant rise in its stock today, contrasting with the broader market's modest gains. While the company has shown short-term improvement, its long-term performance remains challenged by declining sales and profits, highlighting difficulties in the pharmaceutical and biotechnology sector.

Anhui Anke Biotechnology (Group) Co., Ltd. saw a rise on June 23, 2026, contrasting with a decline in the broader market. The company, with a market cap of CNY 9,218 million, has faced challenges over the past year, showing a decline while maintaining a dividend yield of 3.14%.

Anhui Anke Biotechnology (Group) Co., Ltd. has recently experienced a change in its stock evaluation, reflecting a more balanced fair valuation. Key financial metrics indicate a P/E ratio of 25 and a solid ROCE of 23.86%, while the stock shows a mixed technical outlook amid a stable dividend yield of 2.04%.

Anhui Anke Biotechnology (Group) Co., Ltd. saw a significant rise on March 27, 2026, contrasting with the broader market. Despite a modest weekly gain, the stock has declined over the past month and year-to-date. The company has a market capitalization of CNY 11,374 million and a dividend yield of 1.53%.

Anhui Anke Biotechnology (Group) Co., Ltd. experienced a notable intraday gain, contrasting with its recent performance trends, including a decline over the past week and month. The company has faced challenges with consecutive negative quarterly results, prompting a potential need for strategic reassessment amid a declining stock performance over multiple years.

Anhui Anke Biotechnology (Group) Co., Ltd. saw a notable decline in its stock today, underperforming the broader market. Over the past week and month, the stock has continued to decrease, with significant long-term losses. The company has faced challenges, including consecutive negative quarterly results and a decrease in profits.